Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

114.54 +1.30 (+1.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Gilead Sciences Inc (NASDAQ:[GILD](https://www.chartmill.com/stock/quote/GILD)): A Dividend Stock Worth Considering
Gilead Sciences Inc (NASDAQ:[GILD](https://www.chartmill.com/stock/quote/GILD)): A Dividend Stock Worth Considering 
Via Chartmill
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
Moderna (MRNA) Reports Earnings Tomorrow: What To Expect
Biotechnology company Moderna (NASDAQ:MRNA) will be announcing earnings results tomorrow before market hours. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
Amgen (AMGN) Reports Earnings Tomorrow: What To Expect
Biotech company Amgen (NASDAQ:AMGN) will be reporting earnings tomorrow afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Earnings Scheduled For April 24, 2025
Via Benzinga
Biogen Earnings: What To Look For From BIIB
Biotech company Biogen (NASDAQ:BIIB) will be announcing earnings results tomorrow before the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence World Trade
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings
Biotech company BioMarin Pharmaceutical (NASDAQ:BMRN) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
Topics Artificial Intelligence World Trade
United Therapeutics (UTHR) To Report Earnings Tomorrow: Here Is What To Expect
Biotechnology company United Therapeutics (NASDAQ:UTHR) will be reporting earnings tomorrow morning. Here’s what to look for. 
Via StockStory
Topics Government World Trade
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
These S&P500 stocks are moving in today's session
Curious about the top performers within the S&P500 index one hour before the close of the markets on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive... 
Via Chartmill
Exploring the top movers within the S&P500 index during today's session.
Curious about the top performers within the S&P500 index in the middle of the day on Monday? Dive into the list of today's session's top gainers and losers for a comprehensive overview. 
Via Chartmill
Incyte (INCY) Q1 Earnings Report Preview: What To Look For
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results tomorrow morning. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
Regeneron (REGN) Reports Earnings Tomorrow: What To Expect
Biotech company Regeneron (NASDAQ:REGN) will be reporting earnings tomorrow morning. Here’s what you need to know. 
Via StockStory
Topics World Trade
Dividend Investor in Mid-50s Making $23,800 A Month Shares Portfolio, Says He Started with $3.50/hour — 'Just 35 Years of Investing'
Via Benzinga
Why Gilead Sciences Stock Slipped Today
Via The Motley Fool
How Is The Market Feeling About Gilead Sciences?
Via Benzinga
Wall Street Rally Pauses, Tesla Heads For Strongest Week In 6 Months: What's Driving Markets Friday?
Wall Street's three-day rally came to a pause on Friday, with major indices hovering near the flatline by midday in New York as caution returned amid mixed signals on U.S.-China trade relations. 
Via Benzinga
Get insights into the top movers in the S&P500 index of Friday's pre-market session.
Get insights into the top gainers and losers in the S&P500 index of Friday's pre-market session. 
Via Chartmill
AbbVie Reports Upbeat Q1 Earnings, Raises 2025 Earnings Forecast: Retail’s Elated
The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira. 
Via Stocktwits
Topics World Trade
Gilead Sciences Q1 Earnings Surpass Analyst Expectations, But Revenue Falls Short Of Estimates: Retail’s Optimistic
The company is eyeing FDA approval for its drug, lenacapavir, for HIV prevention by mid-June. 
Via Stocktwits
Topics Government Stocks
Skechers Posts Weak Revenue, Joins Intel, Gilead Sciences And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
Why Coursera Shares Are Trading Higher By Over 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Alphabet, Intel And 3 Stocks To Watch Heading Into Friday
Via Benzinga
Which S&P500 stocks are moving after the closing bell on Thursday?
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top S&P500 gainers and losers in today's after-hours session. 
Via Chartmill
Gilead (GILD) Q1 2025 Earnings Call Transcript
Via The Motley Fool
Topics Earnings World Trade
Gilead Sciences Stock Slips After Mixed Q1 Results, Lowered FY25 EPS Guidance
Gilead Sciences releases its first-quarter results after Thursday's closing bell. Here's a look at the details from the report. 
Via Benzinga
Gilead Sciences (NASDAQ:GILD) Misses Q1 Revenue Estimates
Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales flat year on year at $6.67 billion. The company’s full-year revenue guidance... 
Via StockStory
Topics Artificial Intelligence
Gilead Sciences' Bread-And-Butter Drug Missed Sales Views. And It's Not The Only One.
Biktarvy sales came in below forecasts. Will Gilead stock be able to shrug it off? 
Via Investor's Business Daily
Nano-Cap BriaCell Confirms Full Resolution Of Lung Metastasis In Breast Cancer Trial, Stock Shoots Higher
BriaCell confirms complete resolution of lung metastasis at 4 months in Phase 1/2a trial using Bria-OTS immunotherapy in advanced breast cancer. 
Via Benzinga
Wall Street Rally Extends Into Third Day: What's Driving Markets Thursday?
U.S. equities are pushing higher for a third straight session, eyeing the longest winning streak since the Trump tariff announcement on April 2, as optimism over corporate earnings and easing trade... 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.